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SUMMARY
Our objective was to evaluate the efficacy of cold coagulation in the treatment of cervical
intraepithelial neoplasia. The study design consisted ofa retrospective review ofcase records of
all women treated with cold coagulation from the colposcopy clinics inception in 1980 to 1994. A
total of725 women received treatment with cold coagulation. All grades ofCIN were treated. 632
(87.1%) hadlongterm negativefollow up. 93(12.6%) ofpatients had abnormal cytological follow
up, but only 45(6.2%) required re-treatment. Within the first year after treatment 52(7.1%)
patientspresentedwithpersistentcytologicalabnormalities,32(4.4%)requiredrepeatedtreatment
forpersistentdyskaryosis.41(5.6%)ofpatientshadrecurrentcytologicalabnormalities,13(1.8%)
required repeated treatment. Recurrence developed between two and 12 years from initial
treatment. One case of cervical carcinoma following treatment with cold coagulation was




designed to destroy an abnormal transformation
zone. It has been successfully used to treat non-
invasive cervical conditions since 1966. This
treatment method was introduced to clinical
practice for the first time by Kurt Semm;' it
became a popular method for the treatment of
CIN. In the1980s it was the second mostpopular
treatment modality, for CIN in the UK. It has,
however, lost some of its popularity due to the
introduction of the Large Loop Excision of the
Transformation Zone (LLETZ) performed under
local anaesthesia. The latter, being an excisional
rnethod, secured the whole transformation zone
for histopathological examination.
Coldcoagulation is asuitabletherapy forthe out-
patientclinic. Itis arelativelypainlessprocedure
requiring minimal or no analgesia. It is also user
and patient friendly having a short treatment
time, and virtually no immediate complications.
All grades of CIN may be treated with cold
coagulation.
The purpose of this study is to evaluate the
efficacy of cold coagulation in the relatively
static population of women treated in Belfast
City Hospital colposcopy clinic.
PATIENTS AND METHODS
We reviewed the notes of patients who had
attended the BCH colposcopy clinic between its
establishment in 1980 and 1994. Patients treated
with cold coagulation were identified and their
medical records and cytology results were
analysed.
The cytological results were obtained from the
BCH Cytology Laboratory computer and the
NorthernIrelandCervical Screening Programme
database.Informationregardingwomenattending
other hospitals after initial treatment with cold
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coagulation at BCH was traced. Microsoft Excel
was used for data analysis.
Standard management at the clinic consisted of
colposcopic examination with confirmatory
biopsy. Visualisation of the complete squamo-
columnarjunctionandexclusionofanysuspicions
of invasion were the criteria required for cold
coagulation treatment. Verbal consent was
routinely obtained prior to treatment.
When suitable, patients were offered treatment
with cold coagulation under local anaesthesia.
Treatment was preceded by punch biopsy. All
grades of CIN were treated in the same way by
application of the Semm coagulator (WISAP,
Germany) to the cervix. The probe heated to
120°C was applied to each part ofthe cervix for
30-40sec.ensuringthatthewholetransformation
zone was destroyed beyond the limit of aceto-
white epithelium. All patients were advised to
apply Sultrin cream (Janssen-Cilag) vaginally,
nightly foroneweekandtoavoidintercourse and
use oftampons for three weeks.
Initially treatment was performed during the
second visit, but as experience developed a "see,
biopsyandtreat"policywasemployed, withonly
lessexperiencedortraineecolposcopists awaiting
biopsy results before treatment.
The pattern of follow up changed over the years
of study, but all patients were followed up by at
least cytological assessment. This was initially
performed at the 3-4 months follow-up visit.
Since 1990 follow-up has been by a standard
pattern ofreview and smearby the hospital at six
months post treatment. If this smear is normal,
the patient attends her GP for a further smear at
six months post treatment. Thereafter yearly
smears are advised.
Patients with positive cytological results were
reviewed colposcopically and various regimens
of management were instituted depending on
colposcopy findings and individual practice.
Failureoftreatmentwasclassifiedintotwogroups
for the purpose of this study; persistent disease
was recognised when abnormalities were
identified between 6-12 months following initial
treatment, recurrent disease if abnormalities
appeared after 12 months.
Further management of patients with abnormal
follow up cytology included repeat cold
coagulation, Large Loop Excision of the
Transformation Zone, cold knife biopsy and
hysterectomy.
RESULTS
Out of 1329 patients attending the colposcopy
clinic 725 (54.5%) patients received treatment
with cold coagulation.
The mean age ofpatients at presentation was 28
years and ranged from 17 to 52 years. 35% of
patients were nulliparous, 18% had one child,
19% hadtwochildren, and 12% hadthreeormore
children.
Distribution ofreferral smearfindings and initial
biopsy results are shown in Figure. 632(87.2%)
patientshaddyskaryoticabnormalitieseradicated
by initial cold coagulation treatment and their
long term cytological follow up was negative.
93(12.8%) patients developedabnormal smearat
some stage after treatment. 52 patients(7.1%)
presented with persistent cytological
abnormalities within the first year of treatment
and 41(5.6%) with recurrent abnormal smears.
FIGURE
Distribution ofreferral smears and biopsies
results, 95% oftreatedpatients had biopsy
taken prior to treatment.
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CINI CIN1 CINIE HPV NOAL OTHER
Of the 52 patients with persistent abnormal
cytological results 27(52%) presented with CIN
III on referral smear, 12(23%) with CIN II and
6(12%) with CIN I, 3(6%) patients had
unclassified CIN.
Ofthese52patientsshowingpersistentcytological
abnormalities 31(4.3% of all treated with cold
coagulation) had further treatment, 20 on the
basis of positive biopsy and 10 on colposcopic
appearance (Table I).
21 patients were given no further treatment and
were considered to have transient cytological
C) The Ulster Medical Society, 2003.
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TABLE I
Management ofpatients withpersistent cytological abnormalities
Smear Biopsy Treatment Recent smear
results No results No No No
HPV 13 No biopsy 8 No treatment 8 N/a-TAH (hist.neg) 1
Negative 7
HPV 5 Cold coagulation 5 Negative 5
CIN 39 Dysplasia 16 Various treatment
(table 3)
No biopsy 4 Cold coagulation 4 Negative 3
BNA 1
No biopsy 6 LLETZ (hist.neg) 6 Negative 5
N/a-TAH (hist.neg) 1
Biopsy negative 2 No treatment 2 Negative 2
Biopsy positive 1 No treatment 1 Negative 1




HPV-human papillomavirus infection, CIN-cervical intraepithelial neoplasia, n/a-not applicable, TAH-total abdominal
hysterectomy, hist.neg - histopathology results negative, LLETZ - large loop excision of the transformation zone.
abnormalities. 17patients ofthisuntreatedgroup
had negative follow up. Three of these patients
havebeenlosttolong termfollowup, onepatient
had negative screening for five years and
presented at sixth year with recurrent low grade
disease. The treatment modalities of those who
receivedsubsequenttreatmentaresummarisedin
Table II.
Hysterectomy was usually offered as a treatment
optionwhenothergynaecologicalproblemswere
present. Of 9 hysterectomies performed seven
uterinespecimensshowednoevidenceofresidual
CIN.
Overall, 40% of patients with persistent
cytologicalabnormalities at4-6monthsfollowing
treatment required no further treatment as
abnormalities revertedtonormal, suggestingthat
the rate of residual disease was less that 7, 1%
already stated.
Recurrent disease was defined as abnormalities
developing more than a year after treatment.
41(5.6%) patients treated with cold coagulation
developed recurrent abnormal smears. These
patients presented between two and 13 years
from initial treatment.
26(3.5%) of them developed abnormal smears
within first 5 years from treatment, a further 12
patients(l.6%) between year 6 and 10, three
patients(O.4%)hadrecurrencemorethen 10years
following treatment (Table III).
Of those with recurrent abnormalities 18(44%)
presentedwithCINIIIonreferralsmear, 8patients
(19%) with CIN II, 6(15%) with CIN I, 5(12%)
with unclassified CIN, 3 (7%) borderlines and 1
(2.4%) with normal cytology.
Outof41 recurrentcytological abnormalities the
majority(26cases) werelowgradeabnormalities:
8 borderline nuclear abnormalities, 8 viral
infections and 10 CIN I. Overall, recurrent
abnormalities included 25 patients with
dyskaryotic smears, 8 with recent borderline
smears and 8 with transient viral changes.
C The Ulster Medical Society, 2003.
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TABLE II
Management of16patients with persistent cytological abnormalities confirmed by biopsy.
Referral smear No Second treatment No Recent smear No
CIN I 1 TAH 1 N/a 1
CIN 11 2 TAH 1 N/a
Cone biopsy 1 Lost from follow up 1




Lost from follow up 1
Not recorded 1 Cone biopsy 1 negative 1
N/a-notapplicable,TAH-totalabdominalhysterectomy, conebiopsy-anyexcisionalsurgery,rad.hyst.-radicalhysterectomy
TABLE III
Management ofpatients with recurrent cytological abnormalities
Recurrent smear No Management No Recent smear No
HPV 8 No treatment 8 negative 8
BNA 8 Awaiting further 8
assessment
CIN I 10 Cone biopsy 3 Negative 3
Cold coagulation 1 Negative 1




CIN II 6 Cone biopsy 2 Negative 2
Cold coagulation 1 Lost 1
Cautery 1 Negative 1
No treatment 2 Negative 2
CIN III 6 Cone biopsy 4 N/a-TAH 3
Lost 1
No treatment 2 Negative 2
CIN unclassified 3 Cone biopsy 1 Negative 1
No treatment 2 Negative 2
N/a -not applicable, TAH - total abdominal hysterectomy, cone biopsy - any excisional surgery
© The Ulster Medical Society, 2003.
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6 patients had recurrent severe dyskaryotic
smears. Allofthempresentedwithinitial,referral
CIN III and recurred within 5 years of initial
treatment. 13(1.8%) patients received treatment
forrecurrentdyskaryosis, 10ofthemweretreated
withexcisional surgery, 3 withablative methods.
28 patients did not receive treatment, 11 ofthem
had low grade, transient abnormalities, 11 had
recentpositivecytology(8borderlineand3CIN I)
andhavebeen awaiting furtherassessment, and6
had transient dyskaryotic smears which reverted
to normal and remain so.
8 patients (1.1%) had complications recorded in
theirnotes: 2vaso-vagalfaints,5cervicalbleeding
related to the biopsy site, and 1 secondary
haemorrhage due to infection.
The only case of invasive disease following
treatmentwithcoldcoagulationoccurredin 1987.
This patient was referred to the clinic in 1984, at
the age of 23 following conisation of cervix for
CIN III in another hospital. Colposcopy showed
widespreaddysplastic changes; smearCINIIand
biopsy CIN II. She was treated with cold
coagulation under general anaesthesia. Follow
upsmearswerepersistentlyabnormal.Thispatient
underwent five further treatments to the cervix
with different modalities for persistent
dyskaryotic abnormalities. The last excision
revealedinvasive squamouscarcinomaofcervix.
She was treated successfully with radical
hysterectomy and has been in regular follow up.




up: 42 emigrated, 64 can't be traced or refuse to
have a smear, 2 died of other causes, 19(2.6%)
patients had hysterectomy performed. 11(1.5%)
patientshaverecentpositive smears: 8borderline
and3 milddyskaryosis. Defaultrateatfirstfollow
up was 12%(87patients). Thesepatients failedto
have first follow-up smear after treatment.
However, 56ofthemhave anup todate smear, 19
emigrated, 2 had TAH and only 7(0.9%) of all
treated patients) of them are truly lost to follow
up.
Overall of 725 patients treated with cold
coagulation 44 patients (6%) received repeated
treatment for persistent or recurrent disease. 10
(1.3%)patients with recent abnormal smearhave
been awaiting further assessment. The success
rate of treatment with cold coagulation in long
term follow up at our colposcopy clinic was
92.7%.
DISCUSSION
A computerised call/re-call system for cervical
screening was established in Northern Ireland in
1989. The results of all smears are held on a
single databank. There are460,000 women aged
20to65eligibleforcervicalscreeninginNorthern
Ireland. Therecommendednormalrecallinterval
is 5 years and women are called to attend for
cervical smearfromtheage 20. Theresponserate
is still low at 67%.2
Every year 80 new cases of cervical carcinoma
(including microinvasion) are detected in
Northern Ireland, giving the prevalence of 9.6
per 100,000 women.2 Of these cases 50% of
women wereunscreened, 7% screened morethan
5 years before the occurrence, 26% had negative
smear 5 years before and 16% had previous
abnormal smear. The latter group consists of
patients treated, who defaulted or who refused
treatment. There was no incidence of invasive
cervical carcinoma among teenagers in Northern
Ireland.
In our setting, cold coagulation has been shown
to be a safe and efficient treatment with a very
lowmorbidityrate. Thisisinkeepingwithearlier
workbyDuncan-3'4'5 Coldcoagulationwasshown
to be well accepted by both patients and
colposcopists. However, it requires a competent
colposcopistandcompliancewithstrictselection
of patients suitable for treatment with cold
coagulationasestablishedbyGordonandDuncan.
Obviously a suspicion of invasion or
unsatisfactory colposcopic assessment excludes
any ablative method of treatment. Gordon and
Duncan3 claimed 95% primary success rate for
CIN III and success rate of 96.5% with single
treatment and 99% following one or more
treatmentswithcoldcoagulationforpatientswith
CIN I and CIN. Our results are comparable with
these studies. Despite these satisfactory results it
has still been questioned whether or not cold
coagulationcanefficiently treatCINlesions. The
long term follow-up with persistent negative
cytology illustrated by this study and those of
Duncanandco-workersconfirmtheeffectiveness
ofthis treatment. Results ofour study indicated a
very low rate(7.1%) of persistent disease, much
lower than reported by Semple.6 He reported
14.8% rate ofpersistent abnormalities following
CIN treatment with all modalities used by 19
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colposcopyclinicsinNorthWest. Therecurrence
rate following treatment with cold coagulation is
very low, 5.6% in our study, with mainly low
grade abnormalities being found at follow-up.
Not surprisingly we found the highest level of
treatment failure among CIN III lesions which
accounted for 42% of referred cases. It is our
opinion that previous treatment to the cervix, as
afactorchangingitsanatomyisacontraindication
for cold coagulation treatment. The only case of
invasive cancer of cervix following treatment
with cold coagulation occurred in a woman who
hadpreviouslyhadtreatmenttohercervix, which
distorted the anatomy preventing the full lesion
from being amenable to cold coagulation,
although it should be noted that several attempts
hadbeen made to excise persistent abnormalities
before she developed invasive disease. During
thestudyperiodtherewere 10casesofcarcinoma
ofcervix diagnosed onhistopathology as aresult
of excisional biopsies, which had not been
colposcopically detected. All of these patients
hadunsatisfactorycolposcopy,thereforehadbeen
considered unsuitable for treatment with cold
coagulation and were treated by excislonal
techniques.
We have not encountered unexpected
histopathology results of microinvasive or
invasive carcinoma from biopsies taken prior to
the cold coagulation treatment.
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